Disease Domain | Count |
---|---|
Nervous System Diseases | 3 |
Endocrinology and Metabolic Disease | 1 |
Immune System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 4 |
Mechanism 5-HT2A receptor antagonists [+4] |
Active Org. |
Originator Org. |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date10 Sep 2014 |
Target |
Mechanism 5-HT receptor agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. US |
First Approval Date15 Apr 2008 |
Mechanism 5-HT1B receptor agonists [+1] |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date05 Apr 1991 |
Start Date03 Jan 2024 |
Sponsor / Collaborator Currax Pharmaceuticals LLCStartup |
Start Date02 Nov 2017 |
Sponsor / Collaborator Currax Pharmaceuticals LLCStartup |
Start Date01 Jan 2015 |
Sponsor / Collaborator Currax Pharmaceuticals LLCStartup [+1] |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Doxepin hydrochloride ( NET x SERT ) | Sleep Initiation and Maintenance Disorders More | Approved |
Sumatriptan Succinate ( 5-HT1B receptor x 5-HT1D receptor ) | Migraine Disorders More | Approved |
Bupropion Hydrochloride/Naltrexone Hydrochloride ( 5-HT2A receptor x DAT x NET x SERT x nAChRs ) | Overweight More | Approved |
Naproxen Sodium/Sumatriptan Succinate ( 5-HT receptor x COX ) | Migraine Disorders More | Approved |